Growth of the Renin-Inhibitors Market to be Propelled by Increasing Frequency of Cardiovascular Diseases Among the Geriatric Population By a Significant CAGR During 2020 – 2028
Research Nester published a report titled “Renin-inhibitor Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers a detailed overview of the renin-inhibitors market terms of market segmentation by product type, application and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis, and Porter’s five force model.
Renin is a proteolytic enzyme that is secreted in response to sympathetic activation, decreased sodium delivery and hypotension by the kidneys to the distal renal tubule. Renin-inhibitors are termed as a group of pharmaceutical drugs used primarily in the treatment of essential hypertension by blocking the activity of renin and causing vasodilatation. The first and second generations of drugs faced problems such as poor bioavailability and lack of potency whereas the third-generation drugs had acceptable oral bioavailability and were potent enough for clinical use. The resin-inhibitor market is segmented by application into below 45, 46-55, 56-65 & above 66, out of which, the age above 66 segment is anticipated to hold the leading market share on the back of the rising cardiovascular diseases and hypertension cases among this segment.
The resin-inhibitor market is anticipated to record a significant CAGR over the forecast period i.e. 2020-2028. Rising awareness about hypertension with growing predominance, fixed-dose blending therapies, escalated epidemic proportions of hypertension, irregular lifestyle with food habits, changing lifestyle, aging regardless of demography, supplemented stress level, along with the rising research and development for the modern drugs are some of the factors anticipated to support the growth of the global renin-inhibitor market.
Regionally, the global renin-inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America It is anticipated that the region will hold the largest share of the global market throughout the forecast period on account of a rise in the prevalence of hypertension and chronic kidney disorders.
Frequency of Cardiovascular Diseases Among the Geriatric Population
Increasing frequency of cardiovascular diseases among the geriatric population as aged individuals continue to become prone to hypertension and other cardiovascular complications, coupled with the increasing need for the early diagnosis of such diseases and the upsurge in research related to antihypertensive drugs in developing economies along with pulmonary hypertensive practices offering training programs for people are some of the factors anticipated to drive the growth of the global renin-inhibitors market.
However, side effects of drugs and recent patent expirations are expected to operate as key restraints to the growth of the renin-inhibitor market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the renin-inhibitor market which includes company profiling of Johnson & Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), Bio-Rad Laboratories Inc. (NYSE: BIO), Sanofi (EPA: SAN), Lupin (NSE: LUPIN), Merck & Co. (NYSE: MRK), Astra Zeneca (LON: AZN), Daiichi Sankyo (TYO: 4568), Novartis (SWX: NOVN) and Boehringer Ingelheim International GmbH. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials, and recent news and developments. On the whole, the report depicts a detailed overview of the renin-inhibitor marketthat will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities, and other stakeholders to align their market-centric strategies according to the ongoing and expected trends in the future.